This study, called KYSA-6, is looking at a treatment called KYV-101 for people with generalized myasthenia gravis (a chronic autoimmune disease causing muscle weakness). KYV-101 is a type of CAR T-cell therapy that targets CD19, aiming to reduce the B cells that play a role in myasthenia gravis. The study will compare KYV-101 to standard care. To join, you must be between 18 and 75 years old, have specific autoantibodies (AChR or MuSK), and certain scores on MG-ADL and QMG tests. Researchers will measure how safe KYV-101 is over 18 months and how well it improves daily activities (MG-ADL scores) over 24 weeks. The study is currently recruiting 66 participants, but its status is unclear.

Study design

This interventional study plans to enroll 66 participants. It compares KYV-101 treatment to standard of care, with an optional crossover for standard care participants to receive KYV-101.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track safety for 18 months and measure treatment effectiveness for 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.